EZH2 promotes proliferation and invasiveness of prostate cancer cells

The transcriptional repressor EZH2 is implicated in control of cell proliferation in embryonic, immortalized and transformed cells. EZH2 expression in prostate cancer correlates with progression to hormone‐refractory and metastatic disease, but it is unknown whether EZH2 plays a specific role in the acquisition of an advanced prostate cancer phenotype.

[1]  T. Ochiya,et al.  Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[2]  P. V. van Diest,et al.  Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. , 2003, Neoplasia.

[3]  John T. Wei,et al.  Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. , 2005, Cancer cell.

[4]  B. Ness,et al.  The polycomb group protein enhancer of zeste homolog 2 (EZH2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype , 2005, Oncogene.

[5]  K. Helin,et al.  Polycomb Group Proteins in Cell Cycle Progression and Cancer , 2004, Cell cycle.

[6]  T. Utsunomiya,et al.  Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma , 2005, British Journal of Cancer.

[7]  A. Otte,et al.  Gene repression by Polycomb group protein complexes: a distinct complex for every occasion? , 2003, Current opinion in genetics & development.

[8]  Tapio Visakorpi,et al.  The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late‐stage prostate cancer , 2006, Genes, chromosomes & cancer.

[9]  C. Allis,et al.  Translating the Histone Code , 2001, Science.

[10]  J. Köllermann,et al.  Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. , 2005, International journal of molecular medicine.

[11]  S. Merajver,et al.  The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells. , 2005, Neoplasia.

[12]  V. Rotter,et al.  Activated p53 suppresses the histone methyltransferase EZH2 gene , 2004, Oncogene.

[13]  C. Meijer,et al.  Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis. , 2004, Neoplasia.

[14]  R. Willemze,et al.  The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma , 2001, British journal of haematology.

[15]  Arul M Chinnaiyan,et al.  Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. , 2003, Journal of the National Cancer Institute.

[16]  Rosalind Eeles,et al.  Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome , 2004, Oncogene.

[17]  C. Meijer,et al.  Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. , 2001, Blood.

[18]  Lei Ding,et al.  Enhancer of Zeste 2 as a marker of preneoplastic progression in the breast. , 2006, Cancer research.

[19]  N. Palavan-Unsal,et al.  Increased Expression of EZH2, a Polycomb Group Protein, in Bladder Carcinoma , 2005, Urologia Internationalis.

[20]  D. Tindall,et al.  Androgen receptor signaling in androgen-refractory prostate cancer. , 2001, Journal of the National Cancer Institute.

[21]  R. Hoffman,et al.  Essential Role for Activation of the Polycomb Group (PcG) Protein Chromatin Silencing Pathway in Metastatic Prostate Cancer , 2006, Cell cycle.

[22]  G. Murphy,et al.  LNCaP model of human prostatic carcinoma. , 1983, Cancer research.

[23]  D. Reinberg,et al.  Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[24]  R. Kingston,et al.  Mechanisms of transcriptional memory , 2001, Nature Reviews Molecular Cell Biology.

[25]  C. Kleer,et al.  The Polycomb group protein Enhancer of Zeste 2: its links to DNA repair and breast cancer , 2006, Journal of Molecular Histology.

[26]  Stephen A Boorjian,et al.  Increased Expression of the Polycomb Group Gene, EZH2, in Transitional Cell Carcinoma of the Bladder , 2005, Clinical Cancer Research.

[27]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[28]  T. Golub,et al.  Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. , 2006, Cancer research.

[29]  Kristian Helin,et al.  EZH2 is downstream of the pRB‐E2F pathway, essential for proliferation and amplified in cancer , 2003, The EMBO journal.

[30]  Debashis Ghosh,et al.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Christoph Wülfing,et al.  Polycomb Group Protein Ezh2 Controls Actin Polymerization and Cell Signaling , 2005, Cell.

[32]  K. Yanagihara,et al.  Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer , 2006, Cancer science.

[33]  O. Hobert,et al.  Interaction of Vav with ENX-1, a putative transcriptional regulator of homeobox gene expression , 1996, Molecular and cellular biology.

[34]  Paul Tempst,et al.  Different EZH2-containing complexes target methylation of histone H1 or nucleosomal histone H3. , 2004, Molecular cell.

[35]  S. Merajver,et al.  Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues. , 2006, Cancer research.

[36]  M. Wirth,et al.  Quantitative multi‐gene expression profiling of primary prostate cancer , 2006 .

[37]  Johan Eide,et al.  Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  C. Meijer,et al.  Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease. , 2000, The American journal of pathology.

[39]  V. Reinke,et al.  Regulation of tissue-specific and extracellular matrix-related genes by a class I histone deacetylase. , 2005, Molecular cell.

[40]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.